VEGFA and glioblastoma: In order to improve the delivery and efficacy of CAR-T cells, anti-VEGF therapy was combined with i.v. EGFRvIII CAR-T cells in immunocompetent mice bearing orthotopic GBM tumors from CTA2 and GSC500 cell lines that were engineered to express EGFRvIII.